BioAtla Inc (NASDAQ: BCAB) is 21.95% higher on its value in year-to-date trading and has touched a low of $1.24 and a high of $4.07 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BCAB stock was last observed hovering at around $2.61 in the last trading session, with the day’s gains setting it 0.39%.
Currently trading at $3.00, the stock is 12.15% and 5.10% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.31 million and changing 14.94% at the moment leaves the stock 30.18% off its SMA200. BCAB registered -22.48% loss for a year compared to 6-month gain of 102.70%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 14.29% loss in the last 1 month and extending the period to 3 months gives it a 17.65%, and is -4.15% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.49% over the week and 13.77% over the month.
BioAtla Inc (BCAB) has around 65 employees, a market worth around $144.33M and $0.00M in sales. Distance from 52-week low is 141.94% and -26.25% from its 52-week high. The company has generated returns on investments over the last 12 months (-237.85%).
The EPS is expected to grow by 31.83% this year
The shares outstanding are 48.08M, and float is at 38.78M with Short Float at 13.74%.
BioAtla Inc (BCAB) Insider Activity
The most recent transaction is an insider purchase by MCBRINN SYLVIA, the company’s Director. SEC filings show that MCBRINN SYLVIA bought 4,000 shares of the company’s common stock on Dec 26 ’23 at a price of $2.33 per share for a total of $9320.0. Following the purchase, the insider now owns 15125.0 shares.
BioAtla Inc disclosed in a document filed with the SEC on Dec 20 ’23 that SHORT JAY M PHD (Chief Executive Officer) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Dec 20 ’23 and was made at $2.14 per share for $0.11 million. Following the transaction, the insider now directly holds 1.44 million shares of the BCAB stock.
Still, SEC filings show that on Dec 19 ’23, STEINMAN LAWRENCE (Director) acquired 20,000 shares at an average price of $2.05 for $41048.0. The insider now directly holds 38,459 shares of BioAtla Inc (BCAB).
